serum proteomics | CancerGRACE

Can we predict which patients will benefit from Tarceva based on a blood test?

Article

Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.

[powerpress]

Read more about Can we predict which patients will benefit from Tarceva based on a blood test?

Can we predict which patients will benefit from Tarceva based on a blood test?

Stay up to date on the latest news, community discussions, and updates

Welcome!